252 related articles for article (PubMed ID: 25450326)
1. [Atherogenic dyslipidemia and residual risk. State of the art in 2014].
Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X;
Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326
[TBL] [Abstract][Full Text] [Related]
2. Residual macrovascular risk in 2013: what have we learned?
Fruchart JC; Davignon J; Hermans MP; Al-Rubeaan K; Amarenco P; Assmann G; Barter P; Betteridge J; Bruckert E; Cuevas A; Farnier M; Ferrannini E; Fioretto P; Genest J; Ginsberg HN; Gotto AM; Hu D; Kadowaki T; Kodama T; Krempf M; Matsuzawa Y; Núñez-Cortés JM; Monfil CC; Ogawa H; Plutzky J; Rader DJ; Sadikot S; Santos RD; Shlyakhto E; Sritara P; Sy R; Tall A; Tan CE; Tokgözoğlu L; Toth PP; Valensi P; Wanner C; Zambon A; Zhu J; Zimmet P;
Cardiovasc Diabetol; 2014 Jan; 13():26. PubMed ID: 24460800
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of the metabolic syndrome.
Ceska R
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S2-4. PubMed ID: 17935057
[TBL] [Abstract][Full Text] [Related]
4. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
5. Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?
Halcox J; Misra A
Metab Syndr Relat Disord; 2015 Feb; 13(1):1-21. PubMed ID: 25402738
[TBL] [Abstract][Full Text] [Related]
6. The lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit S
Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
[TBL] [Abstract][Full Text] [Related]
7. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception.
Plana N; Ibarretxe D; Cabré A; Ruiz E; Masana L
Clin Investig Arterioscler; 2014; 26(6):274-84. PubMed ID: 24931442
[TBL] [Abstract][Full Text] [Related]
9. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
[TBL] [Abstract][Full Text] [Related]
10. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
Fruchart JC; Sacks FM; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P;
Diab Vasc Dis Res; 2008 Nov; 5(4):319-35. PubMed ID: 18958843
[TBL] [Abstract][Full Text] [Related]
11. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.
Pedro-Botet J; Ascaso JF; Blasco M; Brea Á; Díaz Á; Hernández-Mijares A; Pintó X; Millán J;
Clin Investig Arterioscler; 2020; 32(5):209-218. PubMed ID: 32037300
[TBL] [Abstract][Full Text] [Related]
12. Atherogenic dyslipidemia.
Hayden MR
J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
[No Abstract] [Full Text] [Related]
13. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications.
Cannon CP
Am J Cardiol; 2008 Dec; 102(12A):5L-9L. PubMed ID: 19084083
[TBL] [Abstract][Full Text] [Related]
14. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Chapman MJ; Redfern JS; McGovern ME; Giral P
Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
[TBL] [Abstract][Full Text] [Related]
15. [The role of atherogenic dyslipidaemia in clinical practice guidelines].
Pedro-Botet J; Mantilla-Morató T; Díaz-Rodríguez Á; Brea-Hernando Á; González-Santos P; Hernández-Mijares A; Pintó X; Millán Núñez-Cortés J
Clin Investig Arterioscler; 2016; 28(2):65-70. PubMed ID: 26949069
[TBL] [Abstract][Full Text] [Related]
16. Control of the overall lipid profile.
Blasco M; Ascaso JF;
Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():34-41. PubMed ID: 31785850
[TBL] [Abstract][Full Text] [Related]
17. [The real measurement of non-HDL-cholesterol: Atherogenic cholesterol].
Millán J; Hernández-Mijares A; Ascaso JF; Blasco M; Brea A; Díaz Á; González-Santos P; Mantilla T; Pedro-Botet J; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):265-270. PubMed ID: 27633523
[TBL] [Abstract][Full Text] [Related]
18. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
Chan DC; Barrett PH; Watts GF
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
Brea Hernando ÁJ
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
[TBL] [Abstract][Full Text] [Related]
20. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
